In a docking screen of FDA-approved drugs, examorelin was one of four drugs, with ornipressin, lypressin and polymyxin B1, predicted to bind strongly in the binding pockets of both forms of SARS-CoV-2 RdRp.
In plain wordsIn a computer screen, examorelin was among four drugs predicted to bind strongly to a SARS-CoV-2 enzyme.
- Peptide
- Hexarelin
- Outcome
- Not applicablePredicted binding to SARS-CoV-2 RdRp
- Study
n: not reported in source
SARS-CoV-2 RdRp structure with cofactors nsp7 and nsp8- Outcome group
- Antiviral activity · Infection
Source sentences
Interestingly, some of the identified drugs (Ornipressin, Lypressin, Examorelin, Polymyxin B1) bind strongly within the binding pockets of both forms of RdRp.
1 context sentence(design, population, supporting numbers)
This study explored the FDA approved database of 7922 molecules and screened against the core polymerase along with cofactors.
In this study, Hexarelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Hexarelin.